Companies › Jiangsu Hansoh Pharmaceutical
12 active drug programs in 32 registered trials: 17 Phase 1, 8 Phase 3, 6 Phase 2, 1 Phase 4; Oncology, Other, Hematology, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tenofovir Amibufenamide (TMF) Nucleotide reverse transcriptase inhibitor (NRTi) - prodrug of tenofovir | POLR2A | Phase 4 | Hepatitis B, Chronic | Sep 2029 |
| HS-10504 EGFR C797S mutation-targeting tyrosine kinase inhibitor | EGFR | Phase 3 | Advanced or Metastatic NSCLC; Locally Advanced or Metastatic NSCLC | Dec 2026 |
| Aumolertinib Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 3 | Non-small Cell Lung Cancer; Non Small Cell Lung Cancer; Non-Small Cell Lung Cancer; Lung Cancer … | Jan 2027 |
| HS-10365 RET inhibitor | RET | Phase 2 | Nonsmall Cell Lung Cancer | Aug 2027 |
| HS-20118 | – | Phase 1 | Psoriasis; Healthy Participants | Dec 2026 |
| HS-10542 | – | Phase 1 | Healthy; Paroxysmal Nocturnal Hemoglobinuria | May 2027 |
| HS-10516 HIF-2α inhibitor | HIF2A | Phase 1 | Advanced Clear Cell Renal Cell Carcinoma; Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma | Jul 2027 |
| HS-10386 | – | Phase 1 | Advanced Solid Tumor | Oct 2027 |
| HS-10566 Intravesical gemcitabine delivery system | RRM1, RRM2, DCK | Phase 1 | High-risk Non-muscle-invasive Bladder Cancer | Apr 2028 |
| HS-10506 | – | Phase 1 | Hepatic Impairment (Moderate or Mild) & Normal Hepatic Function | Jun 2028 |
| HS-10502 PARP1-specific selective inhibitor | PARP1 | Phase 1 | Ovarian Cancer; Recurrent Ovarian Cancer | – |
| HS-20094 GLP-1 receptor agonist | – | Phase 1 | Overweight or Obesity | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04923906 | Aumolertinib | Phase 3 | Non-small Cell Lung Cancer | Oncology | Jun 2024 |
| NCT06926413 | Aumolertinib | Phase 1 | Non Small Cell Lung Cancer | Oncology | Oct 2025 |
| NCT06924398 | Aumolertinib | Phase 2 | Lung Cancer (NSCLC) | Oncology | Dec 2025 |
| NCT07040046 | HS-10542 | Phase 1 | Healthy | Other | Dec 2025 |
| NCT06300424 | Aumolertinib | Phase 2 | Non Small Cell Lung Cancer | Oncology | Jan 2026 |
| NCT07057674 | HS-20094 | Phase 1 | Overweight or Obesity | Metabolic and endocrine | Feb 2026 |
| NCT07033234 | HS-20118 | Phase 1 | Psoriasis | Immunology | Mar 2026 |
| NCT05740956 | HS-10502 | Phase 1 | Ovarian Cancer | Oncology | Apr 2026 |
| NCT06769425 | HS-10502 | Phase 1 | Recurrent Ovarian Cancer | Oncology | May 2026 |
| NCT06846710 | HS-20118 | Phase 1 | Psoriasis | Immunology | Jul 2026 |
| NCT07896915 | HS-20118 | Phase 1 | Healthy Participants | Other | Dec 2026 |
| NCT04841811 | Aumolertinib | Phase 3 | Lung Cancer | Oncology | Dec 2026 |
| NCT06461156 | HS-10504 | Phase 1 | Locally Advanced or Metastatic NSCLC | Oncology | Dec 2026 |
| NCT04951635 | Aumolertinib | Phase 3 | Non-small Cell Lung Cancer | Oncology | Jan 2027 |
| NCT06947811 | Aumolertinib | Phase 1 | EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor | Other | Mar 2027 |
| NCT06951464 | Aumolertinib | Phase 2 | Non-Small Cell Lung Cancer | Oncology | May 2027 |
| NCT07470762 | HS-10542 | Phase 1 | Paroxysmal Nocturnal Hemoglobinuria | Hematology | May 2027 |
| NCT06043973 | Aumolertinib | Phase 3 | Advanced Non-small Cell Lung Cancer | Oncology | Jun 2027 |
| NCT07097935 | HS-10516 | Phase 1 | Advanced Clear Cell Renal Cell Carcinoma | Oncology | Jul 2027 |
| NCT06147570 | HS-10365 | Phase 2 | Nonsmall Cell Lung Cancer | Oncology | Aug 2027 |
| NCT05911464 | HS-10386 | Phase 1 | Advanced Solid Tumor | Oncology | Oct 2027 |
| NCT05800223 | Aumolertinib | Phase 3 | Non-small Cell Lung Cancer Metastatic | Oncology | Dec 2027 |
| NCT07130916 | Aumolertinib | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Dec 2027 |
| NCT04685070 | Aumolertinib | Phase 2 | Non-small Cell Lung Cancer Stage III | Oncology | Dec 2027 |
| NCT07468851 | HS-10566 | Phase 1 | High-risk Non-muscle-invasive Bladder Cancer | Oncology | Apr 2028 |
| NCT07844967 | HS-10506 | Phase 1 | Hepatic Impairment (Moderate or Mild) & Normal Hepatic Function | Oncology | Jun 2028 |
| NCT06553339 | HS-10516 | Phase 1 | Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma | Oncology | Jul 2028 |
| NCT07754123 | HS-10504 | Phase 3 | Advanced or Metastatic NSCLC | Oncology | Aug 2028 |
| NCT05768490 | Aumolertinib | Phase 3 | Brain Metastases | Oncology | Dec 2028 |
| NCT07624487 | Aumolertinib | Phase 2 | Lung Adenocarcinoma Metastatic | Oncology | Dec 2028 |
| NCT04687241 | Aumolertinib | Phase 3 | Non-small Cell Lung Cancer | Oncology | Jan 2029 |
| NCT06743438 | Tenofovir Amibufenamide (TMF) | Phase 4 | Hepatitis B, Chronic | Infectious disease | Sep 2029 |
AstraZeneca Shanghai Henlius Biotech Chia Tai Tianqing Pharmaceutical Group Allist Pharmaceuticals Johnson & Johnson (Janssen) Dizal Pharmaceuticals Betta Pharmaceuticals Henan Genuine Biotech Merck & Co. (MSD) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
Sunshine Lake Pharma Abbisko Therapeutics Haisco Pharmaceutical Group Jiangsu Simcere Pharmaceutical Sichuan Kelun-Biotech Biopharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.